1. Home
  2. ARTV vs NEPH Comparison

ARTV vs NEPH Comparison

Compare ARTV & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARTV
  • NEPH
  • Stock Information
  • Founded
  • ARTV 2019
  • NEPH 1997
  • Country
  • ARTV United States
  • NEPH United States
  • Employees
  • ARTV N/A
  • NEPH N/A
  • Industry
  • ARTV
  • NEPH Medical/Dental Instruments
  • Sector
  • ARTV
  • NEPH Health Care
  • Exchange
  • ARTV NYSE
  • NEPH Nasdaq
  • Market Cap
  • ARTV 39.0M
  • NEPH 36.1M
  • IPO Year
  • ARTV 2024
  • NEPH 2004
  • Fundamental
  • Price
  • ARTV $1.61
  • NEPH $4.03
  • Analyst Decision
  • ARTV Strong Buy
  • NEPH Buy
  • Analyst Count
  • ARTV 8
  • NEPH 1
  • Target Price
  • ARTV $18.14
  • NEPH $5.00
  • AVG Volume (30 Days)
  • ARTV 303.9K
  • NEPH 67.9K
  • Earning Date
  • ARTV 08-28-2025
  • NEPH 08-07-2025
  • Dividend Yield
  • ARTV N/A
  • NEPH N/A
  • EPS Growth
  • ARTV N/A
  • NEPH N/A
  • EPS
  • ARTV N/A
  • NEPH 0.08
  • Revenue
  • ARTV N/A
  • NEPH $15,517,000.00
  • Revenue This Year
  • ARTV N/A
  • NEPH $17.06
  • Revenue Next Year
  • ARTV N/A
  • NEPH $12.20
  • P/E Ratio
  • ARTV N/A
  • NEPH $53.08
  • Revenue Growth
  • ARTV N/A
  • NEPH 10.34
  • 52 Week Low
  • ARTV $1.47
  • NEPH $1.36
  • 52 Week High
  • ARTV $17.31
  • NEPH $5.00
  • Technical
  • Relative Strength Index (RSI)
  • ARTV N/A
  • NEPH 56.63
  • Support Level
  • ARTV N/A
  • NEPH $3.83
  • Resistance Level
  • ARTV N/A
  • NEPH $4.39
  • Average True Range (ATR)
  • ARTV 0.00
  • NEPH 0.47
  • MACD
  • ARTV 0.00
  • NEPH -0.07
  • Stochastic Oscillator
  • ARTV 0.00
  • NEPH 43.27

About ARTV ARTIVA BIOTHERAPEUTICS INC

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

Share on Social Networks: